BioSpace News Archive

NuProbe and Weigao Group announced a strategic collaboration, wherein the two parties will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to l

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematologic and oncologic diseases, today presented findings

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.

Rakuten Medical, Inc. (Rakuten Medical) today announced the results of two preclinical studies presented at the American Association for Cancer Research (AACR) Virtual Meeting II. These studies further demonstrate t

Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today plans to utilize its clinical-stage cancer immunotherapy StemVacs™ for treatment of COVID-19 patients. Previously

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to research diseases and develop innovative treatments, today announced five presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from June 22- 24, 2020 .

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced a poster presentation at

TXR-311 was identified, screened and selected as an in vivo candidate and demonstrated efficacy comparable to sorafenib with good tolerability

Eighty-five million U.S. consumers managing food allergies spend more than $19 billion annually on specialty food products to avoid allergic reactions or other health consequences—paying five percent more per month than the average consumer—according to new research released from FARE, the largest private funder of food allergy research in the world.

Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today presented a poster during the 2020 American Association for Cancer Research (AACR) annual meeting to be held